Maravai LifeSciences Holdings, Inc. (MRVI) stock
MRVINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30170% above fair value
$7.28−0.12 (-1.62%)
Close on Nov 17, 2026Market cap $1.89BP/E –Yield –
Maravai LifeSciences profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Maravai LifeSciences's profit margin for the twelve months ending Jun 30, 2026 was -37.1%. For fiscal 2025 it was -70.4%, against -55.9% the year before. The highest annual figure on record is 31.3% in fiscal 2020.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -70.4% | −14.5 |
| FY2024 | Dec 31, 2024 | -55.9% | −14.7 |
| FY2023 | Dec 31, 2023 | -41.2% | −66.1 |
| FY2022 | Dec 31, 2022 | 24.9% | +2.2 |
| FY2021 | Dec 31, 2021 | 22.8% | −8.5 |
| FY2020 | Dec 31, 2020 | 31.3% | +34.4 |
| FY2019 | Dec 31, 2019 | -3.1% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -24.1% | +59.4 |
| Q1 FY2026 | Mar 31, 2026 | -5.7% | +58.2 |
| Q4 FY2025 | Dec 31, 2025 | -71.6% | −25.8 |
| Q3 FY2025 | Sep 30, 2025 | -61.4% | +79.2 |
| Q2 FY2025 | Jun 30, 2025 | -83.5% | −69.4 |
| Q1 FY2025 | Mar 31, 2025 | -63.9% | −45.1 |
| Q4 FY2024 | Dec 31, 2024 | -45.8% | +97.1 |
| Q3 FY2024 | Sep 30, 2024 | -140.6% | −131.0 |
| Q2 FY2024 | Jun 30, 2024 | -14.1% | −4.6 |
| Q1 FY2024 | Mar 31, 2024 | -18.8% | −18.7 |
| Q4 FY2023 | Dec 31, 2023 | -142.9% | −161.3 |
| Q3 FY2023 | Sep 30, 2023 | -9.7% | −32.9 |
| Q2 FY2023 | Jun 30, 2023 | -9.5% | −38.8 |
| Q1 FY2023 | Mar 31, 2023 | -0.1% | −27.5 |
| Q4 FY2022 | Dec 31, 2022 | 18.4% | −6.1 |
| Q3 FY2022 | Sep 30, 2022 | 23.3% | −3.1 |
| Q2 FY2022 | Jun 30, 2022 | 29.3% | +6.8 |
| Q1 FY2022 | Mar 31, 2022 | 27.4% | +11.8 |
| Q4 FY2021 | Dec 31, 2021 | 24.4% | −1.2 |
| Q3 FY2021 | Sep 30, 2021 | 26.3% | −18.0 |
| Q2 FY2021 | Jun 30, 2021 | 22.6% | +19.5 |
| Q1 FY2021 | Mar 31, 2021 | 15.6% | −30.3 |
| Q4 FY2020 | Dec 31, 2020 | 25.6% | – |
| Q3 FY2020 | Sep 30, 2020 | 44.3% | – |
| Q2 FY2020 | Jun 30, 2020 | 3.0% | – |
| Q1 FY2020 | Mar 31, 2020 | 45.9% | – |
See a number that looks wrong?